Jafar Akbari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jafar Akbari has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Alipour
Community Medicine Department, Medical Faculty, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications - Adeleh Sahebnasagh
Clinical Research Center, Department of Internal Medicine, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
2 shared publications - Arash Ghasemi
Emam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications - Ebrahim Salehifar
Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications - Majid Saeedi
Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications - Amin Goodarzi
Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Mazandaran University of Medical Sciences, Sari 48157-33971, Iran
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Scilight Press Pty Ltd in Journal of Medicinal Natural Products
- Vol. 2 (4) , 100024
Cumin Essential Oil Nanoemulgel as a Topical Analgesic and Anti-Inflammatory Alternative to NSAIDs
Cuminum cyminum L. (cumin) essential oil (CEO) possesses documented analgesic and anti-inflammatory properties, but its topical application is limited by volatility, instability and low aqueous solubility. This study aimed to develop a CEO nanoemulgel and evaluate its physicochemical characteristics, dermal safety and antinociceptive/anti-inflammatory effects in rodent models. The optimized formulation exhibited nanometric droplet size, uniform distribution and acceptable physical stability. In a rat skin irritation test, repeated application of the CEO nanoemulgel did not produce visible erythema or edema compared with the gel base. In mice, the formulation increased tail-flick latency and reduced nociceptive behaviors in both phases of the formalin test, and histological analysis revealed attenuated inflammatory cell infiltration. These findings suggest that the CEO nanoemulgel has promising antinociceptive and anti-inflammatory activity and appears to be well tolerated in short-term preclinical models. Further studies, including long-term safety assessment, mechanistic analysis and clinical trials, are required before CEO nanoemulgel can be considered for use in humans.
- 15 December 2025
- Published by Scilight Press Pty Ltd in Journal of Medicinal Natural Products
- Vol. 2 (4) , 100024
Open AccessCumin Essential Oil Nanoemulgel as a Topical Analgesic and Anti-Inflammatory Alternative to NSAIDs
Cuminum cyminum L. (cumin) essential oil (CEO) possesses documented analgesic and anti-inflammatory properties, but its topical application is limited by volatility, instability and low aqueous solubility. This study aimed to develop a CEO nanoemulgel and evaluate its physicochemical characteristics, dermal safety and antinociceptive/anti-inflammatory effects in rodent models. The optimized formulation exhibited nanometric droplet size, uniform distribution and acceptable physical stability. In a rat skin irritation test, repeated application of the CEO nanoemulgel did not produce visible erythema or edema compared with the gel base. In mice, the formulation increased tail-flick latency and reduced nociceptive behaviors in both phases of the formalin test, and histological analysis revealed attenuated inflammatory cell infiltration. These findings suggest that the CEO nanoemulgel has promising antinociceptive and anti-inflammatory activity and appears to be well tolerated in short-term preclinical models. Further studies, including long-term safety assessment, mechanistic analysis and clinical trials, are required before CEO nanoemulgel can be considered for use in humans.
- 22 February 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 53 (2) , 318-325
Aloe vera for Prevention of Acute Radiation Proctitis in Colorectal Cancer a Preliminary Randomized, Placebo-Controlled Clinical Trial
Objective To examine the preventive effects of Aloe vera in colorectal cancer patients undergoing radiotherapy. Material and Method Twenty colorectal cancer patients, who received radiation, were randomized to receive Aloe vera 3% or placebo ointment, 1 g twice daily for 6 weeks. At weekly visits, acute radiation proctitis (ARP) was evaluated by Radiation Therapy Oncology Group and clinical presentation criteria as the primary endpoint. We also evaluated secondary endpoints of quality of life, psychosocial status, by applying Hospital Anxiety-Depression (HAD) Scale and laboratory measures of quantitative measurement of C-reactive protein (CRP) as a marker for systemic inflammation. Results There was a significant improvement in the symptom index (before treatment vs. after treatment with Aloe vera) for diarrhea (p = 0.029, median score: 0.5 vs. 0.001). The overall primary and secondary outcomes favored Aloe group, while the measures of toxicity did not achieve a statistical significant difference. The lifestyle score improved significantly with A. vera (p = 004), and they also had a lower depression score in HAD scale (p = 0.008). Furthermore, quantitative CRP decreased significantly during the course of treatment with Aloe vera. Conclusion The use of topical formulation of Aloe vera 3% diminishes the severity of ARP in colorectal cancer patients.
- 22 February 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 53 (2) , 318-325
Aloe vera for Prevention of Acute Radiation Proctitis in Colorectal Cancer a Preliminary Randomized, Placebo-Controlled Clinical Trial
Objective To examine the preventive effects of Aloe vera in colorectal cancer patients undergoing radiotherapy. Material and Method Twenty colorectal cancer patients, who received radiation, were randomized to receive Aloe vera 3% or placebo ointment, 1 g twice daily for 6 weeks. At weekly visits, acute radiation proctitis (ARP) was evaluated by Radiation Therapy Oncology Group and clinical presentation criteria as the primary endpoint. We also evaluated secondary endpoints of quality of life, psychosocial status, by applying Hospital Anxiety-Depression (HAD) Scale and laboratory measures of quantitative measurement of C-reactive protein (CRP) as a marker for systemic inflammation. Results There was a significant improvement in the symptom index (before treatment vs. after treatment with Aloe vera) for diarrhea (p = 0.029, median score: 0.5 vs. 0.001). The overall primary and secondary outcomes favored Aloe group, while the measures of toxicity did not achieve a statistical significant difference. The lifestyle score improved significantly with A. vera (p = 004), and they also had a lower depression score in HAD scale (p = 0.008). Furthermore, quantitative CRP decreased significantly during the course of treatment with Aloe vera. Conclusion The use of topical formulation of Aloe vera 3% diminishes the severity of ARP in colorectal cancer patients.
- Open Access
- 13 May 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-9
Prevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients
Background: Acute radiation-induced proctitis (ARP) is the most common side effect following radiotherapy for malignant pelvic disease. This study evaluated the efficacy of Aloe vera ointment in prevention of ARP. Methods: Forty-two patients receiving external-beam radiotherapy (RT) for pelvic malignancies were randomized to receive either Aloe vera 3% or placebo topical ointment during radiotherapy for 6 weeks. These patients were evaluated based on the severity (grade 0–4) of the following symptoms weekly: rectal bleeding, abdominal/rectal pain, diarrhea, or fecal urgency. RTOG acute toxicity criteria and psychosocial status of the patients were also recorded weekly. Lifestyle impact of the symptoms, and quantitative measurement of C-reactive protein (CRP), an indicator of systemic inflammation, were also measured. Results: The results of present study demonstrated a significant preventive effect for Aloe vera in occurrence of symptom index for diarrhea (p < 0.001), rectal bleeding (p < 0.001), and fecal urgency (p = 0.001). The median lifestyle score improved significantly with Aloe vera during RT (p < 0.001). Intervention patients had a significant lower burden of systemic inflammation as the values for quantitative CRP decreased significantly over 6 weeks of follow-up (p = 0.009). Conclusion: This study showed that Aloe vera topical ointment was effective in prevention of symptoms of ARP in patients undergoing RT for pelvic cancers. Trial registration: IRCT201606042027N6. Registration date: 2016-09-04.
- 13 May 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-9
Open AccessPrevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients
Background: Acute radiation-induced proctitis (ARP) is the most common side effect following radiotherapy for malignant pelvic disease. This study evaluated the efficacy of Aloe vera ointment in prevention of ARP. Methods: Forty-two patients receiving external-beam radiotherapy (RT) for pelvic malignancies were randomized to receive either Aloe vera 3% or placebo topical ointment during radiotherapy for 6 weeks. These patients were evaluated based on the severity (grade 0–4) of the following symptoms weekly: rectal bleeding, abdominal/rectal pain, diarrhea, or fecal urgency. RTOG acute toxicity criteria and psychosocial status of the patients were also recorded weekly. Lifestyle impact of the symptoms, and quantitative measurement of C-reactive protein (CRP), an indicator of systemic inflammation, were also measured. Results: The results of present study demonstrated a significant preventive effect for Aloe vera in occurrence of symptom index for diarrhea (p < 0.001), rectal bleeding (p < 0.001), and fecal urgency (p = 0.001). The median lifestyle score improved significantly with Aloe vera during RT (p < 0.001). Intervention patients had a significant lower burden of systemic inflammation as the values for quantitative CRP decreased significantly over 6 weeks of follow-up (p = 0.009). Conclusion: This study showed that Aloe vera topical ointment was effective in prevention of symptoms of ARP in patients undergoing RT for pelvic cancers. Trial registration: IRCT201606042027N6. Registration date: 2016-09-04.
- Open Access
- 19 September 2015
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 5 (3) , 435-441
The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000
The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000
- 19 September 2015
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 5 (3) , 435-441
Open AccessThe Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000
The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000